narcolepsy
Neurology · 2008–2022
4decisions
4medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 3 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| modafinil, armodafinil First-line treatment of patients with narcolepsy (with and without cataplexy). | May 2022 | Recommended | no section in document |
| modafinil; armodafinil Treatment of narcolepsy with excessive daytime sleepiness. The submission sought to amend PBS restrictions to reflect contemporary guidelines allowing… | Jul 2020 | Deferred | none received |
| armodafinil Treatment of excessive daytime sleepiness associated with narcolepsy. | Nov 2015 | Not recommended | none received |
| modafinil First-line treatment of narcolepsy in patients with excessive daytime sleepiness, recurrent naps, or sleep lapses occurring almost daily for at least 3 months,… | Nov 2008 | Recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.